Clarity Pharmaceuticals Ltd (ASX: CU6)
Australia flag Australia · Delayed Price · Currency is AUD
7.01
-0.34 (-4.63%)
Nov 7, 2024, 4:10 PM AEST

Clarity Pharmaceuticals Company Description

Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development and clinical stage radiopharmaceuticals products in Australia and the United States.

The company’s products include SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2; developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; SAR-bisPSMA, a theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express prostate specific membrane antigen.

It develops theranostic therapy and imaging products for the treatment of cancer in children and adults.

The company was incorporated in 2010 and is based in Sydney, Australia.

Clarity Pharmaceuticals Ltd
Country Australia
Founded 2010
Industry Biotechnology
Sector Healthcare
Employees 50
CEO Michelle Parker

Contact Details

Address:
National Innovation Centre
Sydney, 2015
Australia
Phone 61 2 9209 4037
Website claritypharmaceuticals.com

Stock Details

Ticker Symbol CU6
Exchange Australian Securities Exchange
Fiscal Year July - June
Reporting Currency AUD
ISIN Number AU0000165375
SIC Code 2834

Key Executives

Name Position
Michelle Parker Chief Executive Officer, MD and Executive Director
Dr. Alan John Taylor Ph.D. Executive Chairman
David K. Green BEc., CA Chief Financial Officer
Dr. Colin David Biggin Ph.D. Chief Operating Officer and Non-Independent Executive Director
Dr. Matthew Harris BSc., M.B.A., Ph.D. Chief Scientific Officer
Lisa Sadetskaya Director of Corporate Communications.
Mary Bennett Head of Human Resource
Shaemus Gleason Executive Vice President of Operations
Dr. Othon Gervasio Chief Medical Officer
Robert Vickery Company Secretary